The authors discuss biological markers which could make us better understand the function of biological response modifiers (BRMs) and their efficacy in the advanced melanoma treatment. The demonstration, that BRMs, in vitro, inhibit the growth of melanoma cell lines and that they modulate the expression of melanoma associated antigens (MAA) justify their therapeutic application. While the results obtained with chemotherapeutical substances - alone or in combination - are substantially not very different from the past ones, but interesting progressions are coming from the active immunotherapy. The so called 'adoptive immunotherapy' made of a combination of intratumoral T lymphocytes and interleukin 2, is feasible only for a fraction of patients.
What's new in malignant melanoma - treatment / Prignano F.; Moretti S.; Carli P.; Gianotti B.. - In: ACTA DERMATOVENEROLOGICA ALPINA, PANONICA, ET ADRIATICA. - ISSN 1318-4458. - STAMPA. - 4:(1995), pp. 175-178.
What's new in malignant melanoma - treatment
Prignano F.;Carli P.;
1995
Abstract
The authors discuss biological markers which could make us better understand the function of biological response modifiers (BRMs) and their efficacy in the advanced melanoma treatment. The demonstration, that BRMs, in vitro, inhibit the growth of melanoma cell lines and that they modulate the expression of melanoma associated antigens (MAA) justify their therapeutic application. While the results obtained with chemotherapeutical substances - alone or in combination - are substantially not very different from the past ones, but interesting progressions are coming from the active immunotherapy. The so called 'adoptive immunotherapy' made of a combination of intratumoral T lymphocytes and interleukin 2, is feasible only for a fraction of patients.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
